Reimbursement Exposure
Clearance is not coverage
FDA clearance or CE marking creates permission to sell, but it does not create coding, coverage, payment, or payer confidence. Many IVD companies reach launch with a strong regulatory story and an incomplete reimbursement strategy, leaving commercial teams to explain value before the evidence, billing pathway, and market access plan are ready.
This is where medical device regulatory consulting must connect with reimbursement and commercialization planning. The regulatory pathway, intended use, claims language, clinical evidence package, and launch sequencing all influence how payers evaluate the test after clearance.
Regulatory approval
Establishes that a product can be marketed for a defined intended use and claim set.
Reimbursement approval
Establishes how the test is coded, covered, paid for, and adopted by providers and payers.
What payers look for after clearance
Payers usually need more than analytical validity or regulatory acceptance. They look for evidence that the test changes clinical decision-making, improves outcomes, reduces avoidable cost, or fits a clearly defined care pathway.
A reimbursement-ready launch plan should define the target patient population, economic value proposition, evidence gaps, coding pathway, coverage targets, and provider workflow before commercial launch pressure begins.
Commercial readiness questions to answer early
- • Does the regulatory claim support the payer value story?
- • Is there a clear CPT, PLA, or alternative coding strategy?
- • Which coverage decisions are required before broad adoption?
- • What clinical utility or health economic evidence is still missing?
- • Can sales, medical affairs, and reimbursement teams tell one coherent story?
Build reimbursement into the commercialization plan
The strongest IVD launches treat reimbursement as a commercialization architecture problem, not a post-clearance administrative task. AdvisoryDx helps teams surface these exposure points early so they can align regulatory sequencing, evidence generation, payer strategy, and go-to-market execution.
Take the Assessment